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1Left ventricular ejection fraction (LVEF) remains the most commonly utilized metric of cardiac function1 and has 
been related to outcomes in patients across the spectrum of 
heart failure (HF).2 In patients with HF and reduced ejec-
tion fraction (EF), LVEF had been shown to be predictive of 
cardiovascular death, HF hospitalization, and all-cause mor-
tality in a relatively linear fashion, with those patients at the 
lowest end of the EF spectrum at the greatest risk.3,4
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Background—The angiotensin receptor neprilysin inhibitor sacubitril/valsartan (LCZ696) reduced cardiovascular morbidity 
and mortality compared with enalapril in patients with heart failure (HF) and reduced ejection fraction (EF) in the 
Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure 
(PARADIGM-HF) trial. We evaluated the influence of EF on clinical outcomes and on the effectiveness of sacubitril/
valsartan compared with enalapril.
Methods and Results—Eight thousand three hundred ninety-nine patients with New York Heart Association class II to 
IV HF with reduced EF [left ventricular EF (LVEF) ≤40%] were randomized to sacubitril/valsartan 97/103 mg twice 
daily versus enalapril 10 mg twice daily and followed for a median of 27 months. The primary study end point was 
cardiovascular death or HF hospitalization. LVEF was assessed at the sites and recorded on case report forms. We related 
LVEF to study outcomes and assessed the effectiveness of sacubitril/valsartan across the LVEF spectrum. The mean 
LVEF in PARADIGM-HF, reported by sites, was 29.5 (interquartile range, 25–34). The risk of all outcomes increased 
with decreasing LVEF. Each 5-point reduction in LVEF was associated with a 9% increased risk of cardiovascular death 
or HF hospitalization (hazard ratio, 1.09; 95% confidence interval, 1.05–1.13; P<0.001), a 9% increased risk for CV death 
(hazard ratio, 1.09; 95% confidence interval, 1.04–1.14), a 9% increased risk in HF hospitalization (hazard ratio, 1.09; 
95% confidence interval, 1.04–1.14) and a 7% increased risk in all-cause mortality (hazard ratio, 1.07; 95% confidence 
interval, 1.03–1.12) in adjusted analyses. Sacubitril/valsartan was effective across the LVEF spectrum, with no evidence 
of heterogeneity, when modeled either in tertiles (P interaction=0.87) or continuously (P interaction=0.95).
Conclusions—In patients with HF and reduced EF enrolled in PARADIGM-HF, LVEF was a significant and independent 
predictor of all outcomes. Sacubitril/valsartan was effective at reducing cardiovascular death and HF hospitalization 
throughout the LVEF spectrum.
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT01035255.   
(Circ Heart Fail. 2016;9:e002744. DOI: 10.1161/CIRCHEARTFAILURE.115.002744.)
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The Prospective Comparison of ARNI with ACEI to 
Determine Impact on Global Mortality and Morbidity in Heart 
Failure (PARADIGM-HF) trial randomized patients with 
New York Heart Association class II to IV HF and reduced 
EF (LVEF 40% or less) to the angiotensin receptor neprilysin 
inhibitor sacubitril/valsartan (LCZ696) 200 mg twice daily 
or enalapril 10 mg twice daily, and showed that sacubitril/
valsartan significantly reduced cardiovascular death, HF hos-
pitalization, and all-cause mortality.5 The initial LVEF entry 
criteria were lowered from <40% to ≤35% after ≈1 year of 
study start to ensure that the event rate remained high after the 
release of the Eplerenone in Mild Patients Hospitalization and 
Survival Study in Heart Failure (EMPHASIS-HF) results and 
anticipated increased use of mineralocorticoid receptor antag-
onists.6,7 We assessed the relationship between LVEF and out-
comes and the effectiveness of sacubitril/valsartan across the 
spectrum of EF in PARADIGM-HF.
Methods
Patients and Study Design
Inclusion and exclusion criteria and the design of the PARADIGM-
HF trial have been previously described.5,6 Briefly, enrolled patients 
had New York Heart Association class II to IV HF with reduced EF 
(LVEF ≤40%, which was reduced to 35% via amendment) and were 
clinically stable and on optimal medical therapy including an angio-
tensin converting enzyme (ACE) inhibitor or angiotensin receptor 
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Figure 1. Distribution of left ventricular ejection fraction in the 
Prospective Comparison of ARNI with ACEI to Determine Impact 
on Global Mortality and Morbidity in Heart Failure (PARADIGM-
HF) trial.
Table 1. Baseline Characteristics by Ejection Fraction
<17.5% (n=339)
≥17.5% to <22.5% 
(n=930)
≥22.5% to <27.5% 
(n=1500)
≥ 27.5% to < 32.5% 
(n=2486)
≥ 32.5%  
(n=3143) P
Mean LVEF 14±2 20±1 25±1 30±1 36±2 <0.001
Age 61±13 61±12 62±12 64±11 66±11 <0.001
Female sex 67 (19.8%) 180 (19.4%) 307 (20.5%) 523 (21.0%) 755 (24.0%) 0.004
Body mass index 27.3±5.6 27.2±5.6 27.6±5.4 28.1±5.3 28.9±5.6 <0.001
New York Heart Association class <0.001
  1 26 (7.7%) 66 (7.1%) 91 (6.1%) 105 (4.2%) 101 (3.2%)
  2 234 (69.0%) 680 (73.2%) 1075 (71.7%) 1761 (71.0%) 2168 (69.1%)
  3 76 (22.4%) 178 (19.2%) 328 (21.9%) 595 (24.0%) 841 (26.8%)
  4 3 (0.9%) 5 (0.5%) 5 (0.3%) 18 (0.7%) 29 (0.9%)
Prior HF hospitalization 215 (63.4%) 602 (64.7%) 967 (64.5%) 1553 (62.5%) 1936 (61.6%) 0.25
History of hypertension 197 (58.1%) 578 (62.2%) 906 (60.4%) 1789 (72.0%) 2469 (78.6%) <0.001
White race 174 (51.3%) 529 (56.9%) 837 (55.8%) 1616 (65.0%) 2388 (76.0%) <0.001
Systolic blood pressure 116±14 117±15 119±15 122±15 124±15 <0.001
Diabetes mellitus 115 (33.9%) 315 (33.9%) 505 (33.7%) 863 (34.7%) 1109 (35.3%) 0.82
Heart rate 74±13 73±12 73±11 72±12 72±12 0.20
Ischemic cardiomyopathy 172 (50.7%) 498 (53.5%) 865 (57.7%) 1481 (59.6%) 2019 (64.2%) <0.001
Prior MI 123 (36.3%) 368 (39.6%) 625 (41.7%) 1112 (44.7%) 1406 (44.7%) <0.001
History of AF 84 (24.8%) 273 (29.4%) 451 (30.1%) 873 (35.1%) 1410 (44.9%) <0.001
History of stroke 30 (8.8%) 75 (8.1%) 129 (8.6%) 219 (8.8%) 272 (8.7%) 0.97
Creatinine 1.17±0.30 1.13±0.30 1.12±0.30 1.12±0.30 1.11±0.29 0.012
ICD or CRT-D 86 (25.4%) 212 (22.8%) 285 (19.0%) 367 (14.8%) 293 (9.3%) <0.001
CRT 33 (9.7%) 95 (10.2%) 140 (9.3%) 168 (6.8%) 138 (4.4%) <0.001
Medications
  Diuretics 293 (86.4%) 765 (82.3%) 1254 (83.6%) 1969 (79.2%) 2456 (78.1%) <0.0001
  β-Blockers 318 (93.8%) 856 (92.0%) 1398 (93.2%) 2330 (93.7%) 2908 (92.5%) 0.30
  Digoxin 137 (40.4%) 321 (34.5%) 534 (35.6%) 727 (29.2%) 820 (26.1%) <0.001
  MRA 202 (59.6%) 589 (63.3%) 910 (60.7%) 1413 (56.8%) 1557 (49.5%) <0.001
AF indicates atrial fibrillation; CRT, cardiac resynchronization therapy; HF, heart failure; ICD, implantable cardioverter-defibrillator; LVEF, left ventricular ejection 
fraction; MI, myocardial infarction; and MRA, mineralocorticoid receptor antagonist.
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blocker (ARB), β-blockers if tolerated, and mineralocorticoid recep-
tor antagonist if appropriate. Patients were required to have elevated 
natriuretic peptides, the level of which depended on whether or not 
they had been hospitalized for HF within the previous 12 months. 
Patients were excluded if they had symptomatic hypotension, es-
timated glomerular filtration rate <30 mL/min/1.73 m,2 potassium 
concentration >5.2 mmol/L at screening, or history of angioedema.
After enrollment, participants entered back-to-back single blind 
run-in phases with enalapril titrated to a dose of 10 mg twice daily for 
2 weeks, followed by sacubitril/valsartan, titrated to 97/103 mg twice 
daily for 4 to 6 weeks. Eight thousand three hundred ninety-nine par-
ticipants were then randomized to receive enalapril 10 mg twice daily 
or sacubitril/valsartan 97/103 mg twice daily and were followed for 
a median duration of 27 months. The protocol was approved at each 
participating site by an ethics committee or institutional review board. 
All participants provided written informed consent in accordance with 
established guidelines for the protection of human subjects.
LVEF was measured at the sites and recorded on case report 
forms. In addition to EF, the type of imaging and date of imaging 
were recorded. There were 963 (11.4%) patients randomized with a 
baseline LVEF recorded as >35% and ≤40%, and an additional 1093 
(13%) patients with LVEF recorded as exactly 35%.
Statistical Methods
EF was divided into the following categories: <17.5%, ≥17.5% to 
<22.5%, ≥22.5% to <27.5%, ≥27.5% to <32.5%, ≥32.5% to avoid dig-
it preference for multiples of 5. Baseline characteristics were assessed 
across EF categories and summarized using means and standard devia-
tions or percentages for continuous and binary data, respectively. Tests 
for equality across EF categories were conducted using ANOVA and 
Pearson’s χ2 test. Incidence rates were calculated for each EF category 
and for the primary outcome (cardiovascular death or HF hospitaliza-
tion), cardiovascular death, HF hospitalization, and all-cause mortality 
and expressed as a rate per 100 patient-years. The risk of these out-
comes by EF was assessed in a multivariable model, adjusting for age; 
sex; race; body mass index; New York Heart Association class; prior 
HF hospitalization; prior history of hypertension, myocardial infarc-
tion, stroke, diabetes mellitus, and atrial fibrillation; and baseline use 
of ACE inhibitors or ARB, digoxin, diuretics, β-blockers, mineralo-
corticoid receptor antagonists, implantable cardioverter-defibrillator 
(ICD) and cardiac resynchronization therapy (CRT), NT-proBNP, and 
serum creatinine. We investigated potential nonlinear relationships 
between EF and outcomes through the use of restricted cubic spline 
terms in unadjusted and adjusted Cox models, using 3 knots. We tested 
for interaction between LVEF and treatment in both tertiles and us-
ing LVEF as a continuous variable. We further tested for interaction 
between the elapsed time between the EF measurement and random-
ization and the EF measurement to assess whether more recent mea-
surements were differentially prognostic for the outcomes of interest.
Results
LVEF ranged from 5% to 42% (mean, 29.5±6.2%; median, 30; 
interquartile range, 25–34), and 46% of measurements were 
reported as a multiple of 5 (Figure 1). Echocardiography was 
the predominant imaging mode used to assess EF (96%), and the 
median time between assessment of EF and screening was 27 
days (interquartile range, 2–73 days). Baseline characteristics 
Table 2. Incidence Rates (Per 100 Patient-Years) of Outcomes by Ejection Fraction Group
<17.5% ≥17.5% to <22.5% ≥ 22.5% to <27.5% ≥27.5% to <32.5% ≥32.5%
CV death or HF 
Hospitalization
18.7 (15.6, 24.5) 15.2 (13.5, 17.1) 13.2 (12.0, 14.6) 11.9 (10.9, 12.9) 9.7 (9.0, 10.4)
CV death 10.9 (8.6, 13.6) 9.1 (7.8, 10.5) 7.3 (6.4, 8.3) 6.8 (6.1, 7.5) 5.5 (5.0, 6.1)
HF hospitalization 11.9 (9.4, 14.9) 8.7 (7.5, 10.2) 7.6 (6.7, 8.7) 7.3 (6.6, 8.1) 5.5 (5.0, 6.1)
All-cause death 12.5 (10.1, 15.4) 11.1 (9.7, 12.6) 8.6 (7.6, 9.7) 8.3 (7.6, 9.1) 7.2 (6.6, 7.8)
CV indicates cardiovascular; and HF, heart failure.
Figure 2. Relationship between left ventricular ejection fraction and incident outcomes adjusted for baseline covariates (upper left, pri-
mary end point; upper right, CV death; lower left, HF hospitalization; lower right, all-cause death). CV indicates cardiovascular; and HF, 
heart failure.
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by EF range are shown in Table 1. Patients with lower EF were 
younger and more likely to be male; were less likely to have 
a history of hypertension, prior myocardial infarction, or atrial 
fibrillation; and more likely to be in New York heart Associa-
tion functional class III/IV (than I/II) than patients with a higher 
LVEF. Lower EF patients were more likely to have lower sys-
tolic blood pressure and higher serum creatinine, more likely to 
have received an ICD or CRT, and were more likely to be taking 
diuretics, digoxin, and a mineralocorticoid receptor antagonist.
The incidence of all outcomes was greatest at the lower 
end of the EF spectrum (Table 2; Figure 2). Each 5-point 
reduction in EF was associated with a 9% increased risk of 
cardiovascular death or HF hospitalization (hazard ratio, 1.09; 
95% confidence interval, 1.05–1.13; P<0.001), a 9% increased 
risk for CV death (hazard ratio, 1.09; 95% confidence interval, 
1.04–1.14), a 9% increased risk in HF hospitalization (hazard 
ratio, 1.09; 95% confidence interval, 1.04–1.14), and a 7% 
increased risk in all-cause mortality (hazard ratio, 1.07; 95% 
confidence interval, 1.03–1.12) in adjusted analyses (Table 3). 
There was no evidence of nonlinearity in the relationship 
between LVEF and any of the clinical outcomes in either 
unadjusted or adjusted models.
Sacubitril/valsartan was effective across the spectrum of 
EF for the primary outcome (Figure 3, upper left, P interac-
tion=0.87), for cardiovascular death (Figure 3, upper right, 
P interaction=0.55), for HF hospitalization (Figure 3, lower 
left, P interaction=0.78), and for all-cause mortality (Figure 3, 
lower right, P interaction = 0.93). We observed similar findings 
when the treatment-LVEF interaction was assessed continu-
ously. There was no evidence that the hazard ratio associated 
with EF was modified by the timing of the EF measurement 
relative to randomization.
Discussion
In this post hoc analysis from the PARADIGM-HF trial, we 
found that in patients with HF and reduced EF, LVEF was a 
powerful independent predictor of cardiovascular outcomes and 
all-cause mortality. The angiotensin receptor neprilysin inhibi-
tor sacubitril/valsartan was effective across the LVEF spectrum, 
with no evidence of effect modification for any end point.
LVEF is used as the primary determinant of eligibility for 
many therapies, including most pharmacological therapies for 
HF, CRT, and ICD. In PARADIGM-HF, for which LVEF >40% 
was an exclusion criterion, the relationship between LVEF and 
outcome appeared relatively linear between 15% and 40%, 
with each 5% drop in EF associated with approximately a 10% 
increased risk in cardiovascular death or HF hospitalization after 
adjusting for baseline covariates. These findings are consistent 
with those from the Candesartan in Heart Failure Reduction in 
Mortality (CHARM) program, in which LVEF was a powerful 
predictor of all outcomes in the range up to ≈45%.2
Table 3. Crude and Adjusted Risk of Outcomes Per 5 Points 
of Ejection Fraction
Outcome Crude (HR, 95% CI) Adjusted* (HR, 95% CI)
CV death or HF Hospitalization 1.15 (1.12, 1.19) 1.09 (1.05, 1.13)
CV Death 1.17 (1.12, 1.22) 1.09 (1.04, 1.14)
HF Hospitalization 1.17 (1.12, 1.22) 1.09 (1.04, 1.14)
All-cause Death 1.14 (1.09, 1.18) 1.07 (1.03, 1.12)
CV indicates cardiovascular; CI, confidence interval, HF, heart failure; and 
HR, hazard ratio.
*Adjusted for randomization arm; age; sex; race; region; body mass index; New 
York Heart Association class; systolic blood pressure; heart rate; serum creatinine; 
ischemic status; log(NTproBNP); medical history of hypertension, diabetes 
mellitus, and atrial fibrillation; hospitalization for heart failure, MI, and stroke; 
use of ACEi; use of ARB; concomitant treatments at randomization: implantable 
cardioverter-defibrillator, cardiac resynchronization therapy, diuretic, β-blocker, 
digitalis, and aldosterone antagonist.
28
Figure 3. Treatment effect of sacubitril/valsartan by tertile of left ventricular ejection fraction for all outcomes (upper left, primary end point; 
upper right, cardiovascular death; lower left, HF hospitalization; lower right, all-cause death). CV indicates cardiovascular; and HF, heart failure.
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We found no evidence of effect modification for the effec-
tiveness of sacubitril/valsartan by LVEF, assessed either in 
tertiles or continuously. These findings are also similar to 
those observed in the low LVEF CHARM trials, but are in 
contrast to findings in several other HF trials, including Val-
HeFT, where the benefit of valsartan appeared greatest in the 
lowest EF groups, in a meta-analysis of ACE inhibitor tri-
als,8 and in MERIT-HF, where the benefit of metoprolol was 
greatest in patients with the lowest EF.9 Nevertheless, these 
findings should assuage concerns that patients at either end 
of the LVEF spectrum benefited from therapy with sacubitril/
valsartan to a greater extent than any others and are consistent 
with other analyses from PARADIGM-HF showing that there 
was no heterogeneity based on other measures of HF severity 
using a validated comprehensive risk score.10
At the time the LVEF criteria in PARADIGM-HF were 
changed, a substantial number of patients had already been 
enrolled in the LVEF range between 35% and 40%, representing 
nearly 25% of the enrolled cohort. Despite this change in inclu-
sion criteria, the benefit of sacubitril/valsartan was preserved in 
the upper LVEF range, and the lowering of the LVEF inclusion 
criterion should not be used as a justification to restrict the use 
of sacubitril/valsartan in patients with LVEF between 35% and 
40%. Whether sacubitril/valsartan would benefit patients with 
HF and preserved EF is currently being tested in the ongoing 
PARAGON-HF trial (clinicaltrials.gov NCT01920711).
Some limitations of this analysis should be noted. LVEF 
measurements were made at each site, not centrally, and 
recorded on case report forms. Thus, although echocar-
diography was the predominant mode used to assess LVEF, 
the exact method by which the measurement was made is 
unknown. Moreover, a large percentage of LVEF measure-
ments in PARADIGM-HF were multiples of 5, suggesting 
that these LVEF estimates were made semiquantitatively at 
best. Nevertheless, these limitations are mitigated by the large 
number of patients in PARADIGM-HF and the fact that the 
relationship between LVEF and outcomes was similar to other 
studies in which core laboratory measurements were made.
In summary, we found that LVEF was a potent predictor 
of outcome in patients with HF and reduced EF enrolled in 
PARADIGM-HF, and this relationship was approximately lin-
ear between LVEF of 15% and 40%. Despite the change in 
inclusion criteria lowering the LVEF upper limit to 35% or 
less, approximately a quarter of patients in PARADIGM-HF 
fell within this range. Sacubitril/valsartan was effective at 
reducing cardiovascular death and HF hospitalization through-
out the spectrum of LVEF studied.
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CLINICAL PERSPECTIVE
Sacubitril/valsartan had previously been shown to reduce morbidity and mortality in patients with heart failure and reduced 
ejection fraction compared with enalapril in the PARADIGM-HF trial. We investigated the relationship between ejection 
fraction and outcome, as well as the relationship between ejection fraction and the efficacy of sacubitril/valsartan, in PARA-
DIGM. We found that all outcomes increased with worsening ejection fraction. However, we found no evidence of effect 
modification by ejection fraction for the benefit of sacubitril/valsartan. Patients at the lower end and higher end of the ejec-
tion fraction spectrum benefited equally. These findings suggest that sacubitril/valsartan is effective irrespective of ejection 
fraction in patients with heart failure and reduced ejection fraction.
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